Skip to main content
Premium Trial:

Request an Annual Quote

EuroMed, International AIDS Vaccine Initiative, New York City Economic Development Corporation, SUNY Downstate Medical Center, Midwest BioResearch, Illinois Science + Technology Park, AEW Capital Management, ZKS Real Estate Partners, Edgewater Business Pa

EuroMed Plans Relocation to New York
EuroMed, a designer and manufacturer of wound care management products, announced June 18 that it will relocate its manufacturing facility from Northvale, NJ, to Orangeburg, NY, where it will occupy a 38,000-square-foot facility at 25 Corporate Drive, within a state economic-development “Empire” Zone. It is the company’s first major move since entering the US in 1996.
The company said its move will allow it to expand production of its wound care, ostomy barrier and incontinence products, including its new SureSkin IV hydrocolloid dressing. EuroMed anticipates completing its move by mid-summer. EuroMed said it anticipates the move will allow it to grow its R&D and manufacturing divisions as well as its staff of 94 employees.
Jarl Jensen, president of EuroMed, said in a statement announcing the move that he expects the relocation will "strengthen EuroMed's customer relationships and add value to every customer transaction."

IAVI Signs Lease to Become First Tenant in New Bioscience Center in Brooklyn
The International AIDS Vaccine Initiative has agreed to lease 36,000 square feet at BioBAT, a new 486,000 square foot bioscience center to be housed at the Brooklyn Army Terminal in the Sunset Park section of Brooklyn. IAVI becomes the first tenant at BioBAT, a collaboration between New York City Economic Development Corporation and SUNY Downstate Medical Center through the SUNY Research Foundation.
IAVI plans to use its new space to relocate its laboratory focused exclusively on accelerating the development of AIDS vaccines. The lab would be moved in the first quarter of 2008 from its current temporary location within SUNY Downstate. The city and New York state are providing $54.5 million toward the creation of BioBAT, with the city providing its $12.5 million portion for the construction of IAVI's space.
The lab is designed to accelerate the development of technologies that academic institutions lack resources to fund, and which are considered too risky for companies to fund. BioBAT is intended as a bioscience mecca for companies and institutions that outgrow incubator space at SUNY Downstate’s main Brooklyn campus.

Midwest BioResearch Expansion Fuels Move to New Facility
Midwest BioResearch, a provider of outsourced drug disposition and toxicology services, has moved into a 16,000 square-foot laboratory at the Illinois Science + Technology Park in Skokie, Ill., formerly occupied by Pfizer and predecessors Pharmacia and Searle — where ironically many of the company’s top executives worked before forming MBR in 2003 from what was Pharmacia’s Chicago-area R&D facility.
MBR said it outgrew its previous facility in Evanston, Ill., at 1801 Maple Ave., in a June 20 statement announcing the move to the Skokie site: “Fueling the company's expansion is a marked increase in demand for its drug disposition and toxicology services at all stages of drug research and development.”
The company is a contract research organization with more than 40 employees.

AEW/ZKS Venture Snaps Up South San Francisco’s Edgewater Business Park
A joint venture of AEW Capital Management of Boston and ZKS Real Estate Partners purchased Edgewater Business Park, a 167,500-square-foot property in South San Francisco, for $45.25 million or $270 per square foot, according to a June 19 report in the San Francisco Chronicle.
The complex consists of six buildings that primarily are used for research and development. Tenants include Catalyst Biosciences, CoMentis Inc. (formerly Athenagen), ADT Security Systems, KAI Pharmaceuticals, and Toshiba America Medical Systems. The property was reported to be 68 percent leased.
Michael Leggett, Gerry Rohm, Rita Meehan, Brenton Wickam and Randy Scott, all of the commercial real estate brokerage Cornish & Carey Commercial, represented owner Edgewater Business Park in the deal. ZKS will manage the property.

IP Law Firm Moves Within Salt Lake City
Brinks Hofer Gilson & Lione, an intellectual property law firm, is moving its Salt Lake City offices within the city, from the Wells Fargo Center, 299 South Main St., to the Ken Garff Building at 405 South Main St. by July 1.
The law firm will occupy 6,300 square feet of temporary offices at Garff until construction is completed on the 21-story 222 S. Main Street in 2009. Ground is set to be broken this summer for the building, the first high-rise to be built in Salt Lake City in more than a decade.
Founded in 1917, Brinks Hofer Gilson & Lione is based in Chicago and specializes in IP cases in biotechnology and other fields of science and engineering.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.